A new analysis of more than 43,000 adults suggests that GLP-1 drugs, known for weight loss, also have a clear effect on blood pressure.
The findings were presented at the European Congress on Obesity in May 2026. Researchers looked at 32 phase 3 clinical trials. The average participant was 54 years old, and about 59% had high blood pressure at the start. People took GLP-1 medications for about 15 months on average.
The study showed that for every 1% of body weight lost, participants saw a drop in their systolic blood pressure, which is the top number in a reading. The more weight a person lost, the more their blood pressure went down. This link held true regardless of how long the study lasted, a person’s starting weight, sex, or whether they had diabetes.
The connection between excess weight and high blood pressure is well known. This analysis puts a number on that link in the context of these drugs. A 2024 analysis of three large trials found that semaglutide, the active ingredient in Ozempic and Wegovy, lowered the top blood pressure number compared to a placebo. The results were consistent even in people who already had high blood pressure.
A separate 2024 review of 15 trials found similar blood pressure improvements along with weight loss in people taking GLP-1 drugs. A 2023 analysis of 61 clinical trials found that semaglutide produced the greatest blood pressure reduction of any medication studied.
Researchers note that these drugs may also lower blood pressure through other means, even without weight loss. They may relax blood vessels, improve how the kidneys handle salt, and reduce stress signals in the body. This suggests GLP-1 drugs and newer multi-hormone medications may work through two paths: one linked to weight loss, and another that acts directly on the heart and kidneys.
This second path is still being studied. Its existence helps explain why some patients see blood pressure benefits that seem larger than what their weight loss alone would suggest. The newer drugs, which target multiple hormone receptors, add complexity. Researchers are still working to understand which mechanisms drive which effects.
Obesity and high blood pressure often occur together and reinforce each other. They are public health issues that contribute to preventable heart disease and deaths. Clinical guidelines already support managing overweight and obesity as a key strategy for lowering blood pressure.
For the 59% of trial participants who already had high blood pressure, the blood pressure lowering effect was a meaningful outcome on its own. For people taking these drugs mainly for weight loss, understanding this effect adds important context. This is especially relevant given how often obesity and metabolic issues overlap. Visceral fat, in particular, carries risks that go beyond the heart.
The analysis has limits. It used trial-level data, not individual patient data. There was variation across trials in populations and study design. Blood pressure was not the main goal in any of the included trials. Some patients may have also changed their blood pressure medications, which could have affected results.
Several trials are underway to study these effects further. Research is also looking at the acute effects of these drugs on heart and blood vessel function, kidney function, and nerve pathways. Still, the consistency of findings across 32 trials and more than 43,000 participants is hard to dismiss.
GLP-1 drugs and next-generation obesity medications are already changing how weight management is viewed. This analysis adds another layer, showing they may also be useful tools for blood pressure control. This is especially relevant for the large number of people living with both obesity and high blood pressure.
